Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, Schellens JH.

Invest New Drugs. 2007 Feb;25(1):9-19.

PMID:
16633717
2.

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.

Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lázaro LL, Beijnen JH, Schellens JH.

Anticancer Drugs. 2005 Oct;16(9):935-43.

PMID:
16162970
3.

Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry.

Brandon EF, van Ooijen RD, Sparidans RW, Lázaro LL, Heck AJ, Beijnen JH, Schellens JH.

J Mass Spectrom. 2005 Jun;40(6):821-31.

PMID:
15892174
4.

Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.

Nuijen B, Bouma M, Manada C, Jimeno JM, Lazaro LL, Bult A, Beijnen JH.

Invest New Drugs. 2001;19(4):273-81.

PMID:
11561686

Supplemental Content

Loading ...
Support Center